Intravenous ustekinumab maintenance treatment in patients with loss of response to subcutaneous dosing.

ABSTRACT:

Background

Ustekinumab (UST) is indicated for the treatment of Crohn's disease (CD) and Ulcerative Colitis (UC). Despite having shown clinical effectiveness in the real world, some patients may lose response over time or need a higher dose to achieve it. In this context, UST intravenous (IV) maintenance has been proposed.

Objectives

The primary endpoint of our study was to evaluate the efficacy and safety of maintenance IV UST treatment in Inflammatory Bowel Disease (IBD) patients who present with partial response or loss of response to subcutaneous (SC) UST.

Design

We performed a monocentric observational retrospective study including patients with active IBD on maintenance treatment with IV UST.

Methods

The clinical response and remission was analyzed at week

SUBMITTER: Arguelles-Arias F 

PROVIDER: S-EPMC10467174 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature